|1.||Ghigo, Ezio: 1 article (01/2013)|
|2.||Guaraldi, Federica: 1 article (01/2013)|
|3.||Baldini, Chiara: 1 article (01/2013)|
|4.||Tabaro, Isabella: 1 article (01/2013)|
|5.||Di Giacomo, Stellina: 1 article (01/2013)|
|6.||Prencipe, Nunzia: 1 article (01/2013)|
|7.||Gasco, Valentina: 1 article (01/2013)|
|8.||Perez, Cristina: 1 article (01/2013)|
|9.||Carlson, Charles R: 1 article (01/2013)|
|10.||Beccuti, Guglielmo: 1 article (01/2013)|
09/01/1987 - "The overall in vitro response rate (defined as less than 50% survival of tumor colony forming units) for quinocarmycin at 0.1 and 1.0 microgram/ml continuous exposure was 42% and 72%, respectively, which was superior to that of other drugs. "
12/01/1988 - "Antitumor activity of quinocarmycin citrate (KW-2152) against human tumor xenografts serially transplanted into nude mice."
03/01/1987 - "KW-2152 displayed significant antitumor activities against the human tumor xenografts in 3 out of 13 strains (23.1 per cent) at the schedule of q4d X 3, with a daily dose of 7.3 mg/kg. Depending on the schedule of administration, tumor activity was observed in 8 out of 13 strains (61.5 per cent) at a schedule of q2d X 6, with a daily dose of 7.3 mg/kg. SH-2 and SH-9 gastric tumors were sensitive to KW-2152 and growth was completely inhibited with the schedule of q4d X 3, and a daily dose of 7.3 mg/kg. Thus, KW-2152 seems to have a wide antitumor spectrum, and the possible antitumor effects for clinical use, warrant attention."
03/01/1987 - "The antitumor activities of KW-2152, a new isoquinon derivative, were examined in thirteen human tumor xenografts, transplanted into nude mice. "
03/01/1987 - "Antitumor activities of KW-2152, a new isoquinon agent, against human tumor xenografts transplanted into nude mice."
03/15/1987 - "A novel antitumor antibiotic, 2a,3,4,5,6,6a,7,11b-octahydro-11-methoxy-12-methyl-3,6-imino-1H-2-oxa-11 c- azanaphth(1,2,3-cd)azulene-5-carboxylic acid monocitrate (quinocarmycin citrate; KW2152) was selected for investigation in a number of experimental tumor systems because of its efficacy against P388 leukemia. "
|3.||Melanoma (Melanoma, Malignant)
02/15/1995 - "Quinocarmycin monicitrate (KW2152) and its analogue, DX-52-1, demonstrated specificity for melanomas in the National Cancer Institute in vitro human tumor cell line drug screen. "
09/04/1998 - "The hydrocyanated derivative of the antitumor antibiotic quinocarmycin, DX-52-1 (I), exhibits impressive activity against human melanoma xenograft models in vivo. "
|5.||Post-Traumatic Stress Disorders (PTSD)
|4.||Anti-Bacterial Agents (Antibiotics)
|8.||xibenolol (D 32)
|1.||Heterologous Transplantation (Xenotransplantation)